Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Claude Libert

Showing results (21-30 of 245) with videos related to

Pageof 25
Sort By:
European Journal of Immunology|December 7, 2005
How glucocorticoids control their own strength and the balance between pro- and anti-inflammatory mediatorsWim Van Molle, Claude Libert
Cytokine & Growth Factor Reviews|July 6, 2006
Matrix metalloproteinase-8: cleavage can be decisivePhilippe Van Lint, Claude Libert
Journal of Leukocyte Biology|August 22, 2007
Chemokine and cytokine processing by matrix metalloproteinases and its effect on leukocyte migration and inflammationPhilippe Van Lint, Claude Libert
Expert Opinion on Therapeutic Targets|October 23, 2018
Should we target TNF receptors in the intestinal epithelium with glucocorticoids during systemic inflammation?Kelly Van Looveren, Claude Libert
Nature Reviews. Drug Discovery|November 8, 2014
Is there new hope for therapeutic matrix metalloproteinase inhibition?Roosmarijn E Vandenbroucke, Claude Libert
The FEBS Journal|January 24, 2020
Hypoxia-inducible factors in metabolic reprogramming during sepsisTineke Vanderhaeghen, Jolien Vandewalle, Claude Libert
Nature Reviews. Immunology|July 24, 2010
The X chromosome in immune functions: when a chromosome makes the differenceClaude Libert, Lien Dejager, Iris Pinheiro
Cytokine & Growth Factor Reviews|April 28, 2004
Matrilysin (matrix metalloproteinase-7): a new promising drug target in cancer and inflammation?Ben Wielockx, Claude Libert, Carole Wilson
Trends in Genetics : TIG|April 14, 2009
Thirty years of Mus spretus: a promising futureLien Dejager, Claude Libert, Xavier Montagutelli
EMBO Molecular Medicine|December 17, 2020
Turning a pathogen protein into a therapeutic tool for sepsisTineke Vanderhaeghen, Charlotte Wallaeys, Claude Libert
Pageof 25

Showing results (21-30 of 245) with videos related to

Sort By:
Pageof 25
European Journal of Immunology|December 7, 2005
How glucocorticoids control their own strength and the balance between pro- and anti-inflammatory mediatorsWim Van Molle, Claude Libert
Cytokine & Growth Factor Reviews|July 6, 2006
Matrix metalloproteinase-8: cleavage can be decisivePhilippe Van Lint, Claude Libert
Journal of Leukocyte Biology|August 22, 2007
Chemokine and cytokine processing by matrix metalloproteinases and its effect on leukocyte migration and inflammationPhilippe Van Lint, Claude Libert
Expert Opinion on Therapeutic Targets|October 23, 2018
Should we target TNF receptors in the intestinal epithelium with glucocorticoids during systemic inflammation?Kelly Van Looveren, Claude Libert
Nature Reviews. Drug Discovery|November 8, 2014
Is there new hope for therapeutic matrix metalloproteinase inhibition?Roosmarijn E Vandenbroucke, Claude Libert
The FEBS Journal|January 24, 2020
Hypoxia-inducible factors in metabolic reprogramming during sepsisTineke Vanderhaeghen, Jolien Vandewalle, Claude Libert
Nature Reviews. Immunology|July 24, 2010
The X chromosome in immune functions: when a chromosome makes the differenceClaude Libert, Lien Dejager, Iris Pinheiro
Cytokine & Growth Factor Reviews|April 28, 2004
Matrilysin (matrix metalloproteinase-7): a new promising drug target in cancer and inflammation?Ben Wielockx, Claude Libert, Carole Wilson
Trends in Genetics : TIG|April 14, 2009
Thirty years of Mus spretus: a promising futureLien Dejager, Claude Libert, Xavier Montagutelli
EMBO Molecular Medicine|December 17, 2020
Turning a pathogen protein into a therapeutic tool for sepsisTineke Vanderhaeghen, Charlotte Wallaeys, Claude Libert
Pageof 25